Clinical Trials Logo

Filter by:
NCT ID: NCT00947674 Terminated - Ulcerative Colitis Clinical Trials

A Study of Leukocytapheresis (LCAP) in Patients With Ulcerative Colitis (UC)

Start date: May 2009
Phase: Phase 4
Study type: Interventional

This is a prospective, randomized, double-blind, sham treatment controlled multicenter study.

NCT ID: NCT00937664 Terminated - Cancer Clinical Trials

Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine

Start date: July 2009
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD7762 when given with the approved drug gemcitabine based on the side effects experienced by patients that receive both drugs.

NCT ID: NCT00913289 Terminated - Liver Cirrhosis Clinical Trials

Liver Regeneration Therapy Using Autologous Adipose Tissue Derived Stromal Cells

Start date: February 2009
Phase: Phase 1
Study type: Interventional

Mesenchymal stem cells have the capability to differentiate into hepatocytes and will be useful for liver regeneration. Adipose tissue is relatively enriched with mesenchymal stem cells compared to bone marrow tissue. In this trial, eligible liver cirrhosis patients will receive autologous adipose tissue derived stromal cells which include such mesenchymal stem cells.

NCT ID: NCT00900146 Terminated - Clinical trials for Diabetes Mellitus, Type 2

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

Start date: April 2009
Phase: Phase 2/Phase 3
Study type: Interventional

This was a four month dose ranging study followed by a 24 to 48 month extension at the selected dose to characterize the safety and efficacy of the injectable IL-1B (interleukin 1, beta) antagonist canakinumab in the treatment of patients with Type 2 diabetes mellitus (T2DM) already treated on maximum dose metformin.

NCT ID: NCT00895895 Terminated - Alzheimer Disease Clinical Trials

Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease

Start date: May 2009
Phase: Phase 2
Study type: Interventional

The study will evaluate the efficacy and safety of an investigational drug called SAM-531 at three dosage levels. Subjects will receive either one of the 3 dosage levels of SAM-531, donepezil or placebo for the first 24 weeks of the study (period I). Subjects who receive placebo for period I will be assigned to receive the highest dose of SAM-531 SAM-531 for the remaining 28 weeks of the study, while subjects who received one of the three SAM-531 dosage levels or donepezil in period I will continue with the same study drug (period II).

NCT ID: NCT00878501 Terminated - Pain Clinical Trials

Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of AZD1386 in Patients With Osteoarthritis (OA) of the Knee

OA19
Start date: March 2009
Phase: Phase 2
Study type: Interventional

The primary aim of this study is to investigate if AZD1386 is efficacious as an analgesic in patients with osteoarthritis of the knee and at what dose. This will be done by comparing the effect of AZD1386 to placebo ("inactive substance") on pain.

NCT ID: NCT00863980 Terminated - Hypertension Clinical Trials

Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients

KCPS
Start date: April 2009
Phase: N/A
Study type: Interventional

This study is aimed to investigate whether treatment with Telmisartan is more effective than Candesartan in reducing the ischemic cardiovascular events in high-risk patients with cardiovascular disease.

NCT ID: NCT00858364 Terminated - Cancer Clinical Trials

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Start date: July 17, 2009
Phase: Phase 3
Study type: Interventional

This is a study in patients with chemotherapy induced anemia receiving multi-cycle chemotherapy for the treatment of stage IV non-small cell lung cancer (NSCLC). The primary objective of the study is to demonstrate that overall survival (OS) is not worse in participants on darbepoetin alfa treated to a hemoglobin ceiling of 12.0 g/dL compared to participants treated with placebo.

NCT ID: NCT00852397 Terminated - Clinical trials for Acute Coronary Syndrome

A Study to Evaluate the Safety of Apixaban in Acute Coronary Syndrome (ACS) Japanese Patients

Start date: April 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the bleeding safety (the composite endpoint of major and clinically relevant non-major bleeding) of 2 doses of apixaban (2.5 mg BID and 5.0 mg BID) or placebo in combination with standard therapy (aspirin and /or additional antiplatelet therapy) over a 24 week treatment period in selected subjects with recent (≤7 days) acute coronary syndrome.

NCT ID: NCT00849667 Terminated - Ovarian Cancer Clinical Trials

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Start date: April 16, 2009
Phase: Phase 3
Study type: Interventional

This research is being done to find out if Carboplatin and Taxane works better alone or when given with an experimental drug called MORAb-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.